Evaluación de la eficacia y seguridad de PT027 en comparación con PT007 administrado según sea necesario en participantes de 12 a <18 años con asma (ACADIA)
Un estudio de fase IIIb, aleatorizado, doble ciego, multicéntrico, de grupo paralelo, de 52 semanas, que evalúa la eficacia y seguridad de PT027 en comparación con PT007 administrado según sea necesario en participantes de 12 a <18 años con asma (ACADIA)
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This is a randomized, double-blind, multicenter, parallel-group Phase IIIb study with a fixed treatment period of 52 weeks.
The study will consist of 3 periods:
- Screening period (7 to 28 days)
- Treatment period of 52 weeks
- Safety follow-up period (7 to 14 days after the end of treatment [EOT] visit)
Participants who meet the eligibility criteria will be randomly assigned to BDA MDI 160/180 micrograms (μg) or AS MDI 180 μg treatment groups in a 1:1 ratio on top of their own usual maintenance therapy during treatment period.
This study will also include a pharmacokinetic (PK) sub-study with single visit scheduled after the safety follow-up visit in the main study. During PK sub-study, single dose of open-label BDA MDI 160/180 μg will be administered.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: AstraZeneca Clinical Study Information Center
- Número de teléfono: 1-877-240-9479
- Correo electrónico: information.center@astrazeneca.com
Ubicaciones de estudio
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 99508
- Reclutamiento
- Research Site
-
-
Arizona
-
Gilbert, Arizona, Estados Unidos, 85234
- Reclutamiento
- Research Site
-
Phoenix, Arizona, Estados Unidos, 85016
- Reclutamiento
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72202
- Terminado
- Research Site
-
-
California
-
Huntington Beach, California, Estados Unidos, 92647
- Aún no reclutando
- Research Site
-
Huntington Beach, California, Estados Unidos, 92648
- Aún no reclutando
- Research Site
-
Long Beach, California, Estados Unidos, 90806
- Reclutamiento
- Research Site
-
Long Beach, California, Estados Unidos, 90815
- Reclutamiento
- Research Site
-
Madera, California, Estados Unidos, 93636
- Aún no reclutando
- Research Site
-
Mission Viejo, California, Estados Unidos, 92691
- Reclutamiento
- Research Site
-
Moreno Valley, California, Estados Unidos, 92553
- Reclutamiento
- Research Site
-
Orange, California, Estados Unidos, 92868
- Reclutamiento
- Research Site
-
Redondo Beach, California, Estados Unidos, 90277
- Reclutamiento
- Research Site
-
Riverside, California, Estados Unidos, 92506
- Reclutamiento
- Research Site
-
San Diego, California, Estados Unidos, 92123
- Aún no reclutando
- Research Site
-
San Diego, California, Estados Unidos, 92123
- Reclutamiento
- Research Site
-
San Francisco, California, Estados Unidos, 94143
- Retirado
- Research Site
-
Westminster, California, Estados Unidos, 92683
- Reclutamiento
- Research Site
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80206
- Reclutamiento
- Research Site
-
-
Delaware
-
Wilmington, Delaware, Estados Unidos, 19803
- Reclutamiento
- Research Site
-
-
Florida
-
Destin, Florida, Estados Unidos, 32541
- Reclutamiento
- Research Site
-
Jacksonville, Florida, Estados Unidos, 32207
- Reclutamiento
- Research Site
-
Kendall, Florida, Estados Unidos, 33176
- Aún no reclutando
- Research Site
-
Largo, Florida, Estados Unidos, 33777
- Terminado
- Research Site
-
Miami, Florida, Estados Unidos, 33144
- Reclutamiento
- Research Site
-
Miami, Florida, Estados Unidos, 33145
- Reclutamiento
- Research Site
-
Miami, Florida, Estados Unidos, 33185
- Reclutamiento
- Research Site
-
Miami, Florida, Estados Unidos, 33142
- Reclutamiento
- Research Site
-
Miami, Florida, Estados Unidos, 33183
- Reclutamiento
- Research Site
-
Orlando, Florida, Estados Unidos, 32827
- Aún no reclutando
- Research Site
-
Pembroke Pines, Florida, Estados Unidos, 33026
- Reclutamiento
- Research Site
-
Tampa, Florida, Estados Unidos, 33613
- Retirado
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30329
- Reclutamiento
- Research Site
-
Columbus, Georgia, Estados Unidos, 31904
- Reclutamiento
- Research Site
-
Fayetteville, Georgia, Estados Unidos, 30214
- Reclutamiento
- Research Site
-
Snellville, Georgia, Estados Unidos, 30078
- Reclutamiento
- Research Site
-
-
Idaho
-
Meridian, Idaho, Estados Unidos, 83646
- Retirado
- Research Site
-
-
Illinois
-
Normal, Illinois, Estados Unidos, 61761
- Reclutamiento
- Research Site
-
River Forest, Illinois, Estados Unidos, 60305
- Retirado
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Reclutamiento
- Research Site
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Reclutamiento
- Research Site
-
Overland Park, Kansas, Estados Unidos, 66213
- Aún no reclutando
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40217
- Reclutamiento
- Research Site
-
Louisville, Kentucky, Estados Unidos, 40202
- Reclutamiento
- Research Site
-
-
Louisiana
-
Lafayette, Louisiana, Estados Unidos, 70508
- Reclutamiento
- Research Site
-
New Orleans, Louisiana, Estados Unidos, 70121
- Reclutamiento
- Research Site
-
New Orleans, Louisiana, Estados Unidos, 70125
- Reclutamiento
- Research Site
-
-
Maryland
-
Ellicott City, Maryland, Estados Unidos, 21043
- Reclutamiento
- Research Site
-
Lanham, Maryland, Estados Unidos, 20706
- Aún no reclutando
- Research Site
-
Silver Spring, Maryland, Estados Unidos, 20902
- Reclutamiento
- Research Site
-
White Marsh, Maryland, Estados Unidos, 21162
- Reclutamiento
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Aún no reclutando
- Research Site
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Reclutamiento
- Research Site
-
-
Minnesota
-
Mankato, Minnesota, Estados Unidos, 56001
- Activo, no reclutando
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64118
- Reclutamiento
- Research Site
-
Kansas City, Missouri, Estados Unidos, 64108
- Retirado
- Research Site
-
St Louis, Missouri, Estados Unidos, 63108
- Reclutamiento
- Research Site
-
-
Montana
-
Missoula, Montana, Estados Unidos, 59804
- Reclutamiento
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos, 68510
- Reclutamiento
- Research Site
-
Lincoln, Nebraska, Estados Unidos, 68516
- Reclutamiento
- Research Site
-
Omaha, Nebraska, Estados Unidos, 68114
- Reclutamiento
- Research Site
-
-
New Jersey
-
Newark, New Jersey, Estados Unidos, 07103
- Reclutamiento
- Research Site
-
Newark, New Jersey, Estados Unidos, 07103
- Aún no reclutando
- Research Site
-
Northfield, New Jersey, Estados Unidos, 08225
- Reclutamiento
- Research Site
-
Ocean City, New Jersey, Estados Unidos, 07712
- Reclutamiento
- Research Site
-
Paramus, New Jersey, Estados Unidos, 07652
- Reclutamiento
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- Reclutamiento
- Research Site
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Reclutamiento
- Research Site
-
Cortland, New York, Estados Unidos, 13045
- Reclutamiento
- Research Site
-
Hawthorne, New York, Estados Unidos, 10532
- Reclutamiento
- Research Site
-
Hollis, New York, Estados Unidos, 11423
- Retirado
- Research Site
-
New York, New York, Estados Unidos, 10032
- Reclutamiento
- Research Site
-
New York, New York, Estados Unidos, 11355
- Reclutamiento
- Research Site
-
New York, New York, Estados Unidos, 10019
- Retirado
- Research Site
-
Rochester, New York, Estados Unidos, 14607
- Terminado
- Research Site
-
The Bronx, New York, Estados Unidos, 10459
- Reclutamiento
- Research Site
-
The Bronx, New York, Estados Unidos, 10461
- Reclutamiento
- Research Site
-
Vestal, New York, Estados Unidos, 13850
- Reclutamiento
- Research Site
-
Vestal, New York, Estados Unidos, 13850
- Retirado
- Research Site
-
Watertown, New York, Estados Unidos, 13601
- Reclutamiento
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28277
- Retirado
- Research Site
-
Durham, North Carolina, Estados Unidos, 27705
- Aún no reclutando
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Aún no reclutando
- Research Site
-
Columbus, Ohio, Estados Unidos, 43205
- Aún no reclutando
- Research Site
-
Columbus, Ohio, Estados Unidos, 43228
- Reclutamiento
- Research Site
-
Dayton, Ohio, Estados Unidos, 45424
- Reclutamiento
- Research Site
-
Findlay, Ohio, Estados Unidos, 45840
- Reclutamiento
- Research Site
-
Toledo, Ohio, Estados Unidos, 43617
- Reclutamiento
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73120
- Reclutamiento
- Research Site
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Reclutamiento
- Research Site
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Aún no reclutando
- Research Site
-
Yukon, Oklahoma, Estados Unidos, 73099
- Reclutamiento
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15241
- Reclutamiento
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Reclutamiento
- Research Site
-
Rock Hill, South Carolina, Estados Unidos, 29730
- Terminado
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- Reclutamiento
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Reclutamiento
- Research Site
-
-
Texas
-
Austin, Texas, Estados Unidos, 78759
- Reclutamiento
- Research Site
-
Baytown, Texas, Estados Unidos, 77521
- Reclutamiento
- Research Site
-
Beaumont, Texas, Estados Unidos, 77701
- Reclutamiento
- Research Site
-
Beaumont, Texas, Estados Unidos, 77702
- Reclutamiento
- Research Site
-
Bellaire, Texas, Estados Unidos, 77401
- Reclutamiento
- Research Site
-
Corpus Christi, Texas, Estados Unidos, 78411
- Reclutamiento
- Research Site
-
Corsicana, Texas, Estados Unidos, 75110
- Reclutamiento
- Research Site
-
Dallas, Texas, Estados Unidos, 75231
- Reclutamiento
- Research Site
-
Dallas, Texas, Estados Unidos, 75235
- Reclutamiento
- Research Site
-
El Paso, Texas, Estados Unidos, 79912
- Reclutamiento
- Research Site
-
Frisco, Texas, Estados Unidos, 75034
- Retirado
- Research Site
-
Houston, Texas, Estados Unidos, 77099
- Reclutamiento
- Research Site
-
Houston, Texas, Estados Unidos, 77030
- Aún no reclutando
- Research Site
-
Houston, Texas, Estados Unidos, 77065
- Reclutamiento
- Research Site
-
Kerrville, Texas, Estados Unidos, 78028
- Retirado
- Research Site
-
McKinney, Texas, Estados Unidos, 75069
- Reclutamiento
- Research Site
-
San Antonio, Texas, Estados Unidos, 78229
- Reclutamiento
- Research Site
-
San Antonio, Texas, Estados Unidos, 78215
- Reclutamiento
- Research Site
-
San Antonio, Texas, Estados Unidos, 78249
- Aún no reclutando
- Research Site
-
Tyler, Texas, Estados Unidos, 75708
- Terminado
- Research Site
-
-
Utah
-
West Jordan, Utah, Estados Unidos, 84088
- Reclutamiento
- Research Site
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05405
- Reclutamiento
- Research Site
-
-
Virginia
-
Burke, Virginia, Estados Unidos, 22015
- Retirado
- Research Site
-
-
Washington
-
Bellingham, Washington, Estados Unidos, 98225
- Terminado
- Research Site
-
Vancouver, Washington, Estados Unidos, 98664
- Reclutamiento
- Research Site
-
-
-
-
-
Chihuahua City, México, 31000
- Reclutamiento
- Research Site
-
Chihuahua City, México, 31238
- Reclutamiento
- Research Site
-
Guadalajara, México, 44100
- Reclutamiento
- Research Site
-
Guadalajara, México, 44500
- Reclutamiento
- Research Site
-
Monterrey, México, 64465
- Reclutamiento
- Research Site
-
-
-
-
-
Beijing, Porcelana, 100191
- Reclutamiento
- Research Site
-
Beijing, Porcelana, 100050
- Reclutamiento
- Research Site
-
Bengbu, Porcelana, 233004
- Reclutamiento
- Research Site
-
Chengdu, Porcelana, 610066
- Reclutamiento
- Research Site
-
Chongqing, Porcelana, 401122
- Reclutamiento
- Research Site
-
Hohhot, Porcelana, 10050
- Reclutamiento
- Research Site
-
Mianyang, Porcelana, 621000
- Reclutamiento
- Research Site
-
Shanghai, Porcelana, 200433
- Reclutamiento
- Research Site
-
Shanghai, Porcelana
- Reclutamiento
- Research Site
-
Shanghai, Porcelana, 200062
- Reclutamiento
- Research Site
-
Shantou, Porcelana, 515041
- Reclutamiento
- Research Site
-
Shenyang, Porcelana, 110004
- Reclutamiento
- Research Site
-
Shenzhen, Porcelana, 518026
- Reclutamiento
- Research Site
-
Suzhou, Porcelana, 215002
- Reclutamiento
- Research Site
-
Taizhou, Porcelana, 318000
- Reclutamiento
- Research Site
-
Tianjin, Porcelana, 300211
- Reclutamiento
- Research Site
-
Tianjin, Porcelana, 300134
- Reclutamiento
- Research Site
-
Tianjin, Porcelana, 300050
- Reclutamiento
- Research Site
-
Wuhan, Porcelana, 430000
- Reclutamiento
- Research Site
-
Yanji, Porcelana, 133000
- Reclutamiento
- Research Site
-
Yantai, Porcelana, 264000
- Reclutamiento
- Research Site
-
Zhongshan, Porcelana, 528400
- Reclutamiento
- Research Site
-
-
-
-
-
Durban, Sudáfrica, 4001
- Reclutamiento
- Research Site
-
Durban, Sudáfrica, 3630
- Reclutamiento
- Research Site
-
Durban, Sudáfrica, 4092
- Reclutamiento
- Research Site
-
Krugersdorp, Sudáfrica, 1739
- Reclutamiento
- Research Site
-
Middelburg, Sudáfrica, 1055
- Reclutamiento
- Research Site
-
Panorama, Sudáfrica, 7500
- Reclutamiento
- Research Site
-
Somerset West, Sudáfrica, 7130
- Aún no reclutando
- Research Site
-
Welkom, Sudáfrica, 9460
- Reclutamiento
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Confirmed clinical diagnosis of asthma at least 12 months.
-
Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month
- Low-to-high-dose Inhaled corticosteroid(s) (ICS)
- Low-to-high-dose ICS or ICS/long-acting β2-agonist (LABA) with or without one additional maintenance therapy from the following: leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline
-
Receiving inhaled short-acting β2-agonist (SABA) as needed.
-
A documented history of at least one severe asthma exacerbation within 12 months.
-
Use of Sponsor-provided albuterol sulfate inhalation aerosol medication.
-
Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited.
-
Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator.
-
Participants must adhere to protocol specific contraception methods.
-
Negative urine pregnancy test for participants of childbearing potential.
-
Have a BMI < 40 kg/ m^2.
-
Capable of giving assent (signing the assent form) to participate in the study which includes compliance with the requirements and restrictions. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.
Exclusion Criteria:
- Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).
- Experienced > 3 severe asthma exacerbations within 12 months before screening.
- Completed treatment for lower respiratory infection and severe asthma exacerbation with SCS within 4 weeks of screening.
- Upper respiratory infection involving antibiotic treatment not resolved.
- Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana).
- Other significant lung disease, including regular or occasional use of oxygen.
- Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, or gastrointestinal disorders.
- Cancer not in complete remission for at least 5 years.
- History or hospitalization for psychiatric disorder or attempted suicide within one year.
- Significant abuse of alcohol or drugs, in the opinion of the investigator.
- Oral corticosteroid(s) (OCS)/SCS use (any dose and any indication) within 4 weeks before Visit 1 or chronic use of OCS/SCS (≥ 3 weeks use in 3 months prior to Visit 1).
- Use of any oral SABAs within one month.
- Having a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Budesonide/albuterol metered -dose inhaler (BDA MDI)
Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed. |
Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
Otros nombres:
|
|
Comparador activo: Albuterol sulfate metered-dose inhaler (AS MDI)
Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed. |
Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Annualized rate of severe asthma exacerbations (AAER)
Periodo de tiempo: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the AAER in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to first (TTF) severe asthma exacerbation
Periodo de tiempo: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the risk of a first severe asthma exacerbation in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Annualized total systemic corticosteroids (SCS) exposure for treatment of asthma
Periodo de tiempo: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the annualized total SCS exposure for treatment of asthma in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Number of participants with adverse events (AEs) and severe adverse events (SAEs)
Periodo de tiempo: Up to Week 52
|
The safety and tolerability of BDA MDI compared with AS MDI in participants with asthma will be assessed. |
Up to Week 52
|
|
Maximum Observed Concentration (Cmax)
Periodo de tiempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to last quantifiable concentration (AUClast)
Periodo de tiempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to infinity (AUCinf)
Periodo de tiempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time to reach maximum concentration following drug administration (Tmax)
Periodo de tiempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time of last quantifiable concentration (Tlast)
Periodo de tiempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination half-life (t½λz)
Periodo de tiempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination rate constant (λz)
Periodo de tiempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent total body clearance (CL/F)
Periodo de tiempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent volume of distribution based on the terminal phase (Vz/F)
Periodo de tiempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- D6934C00001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Marco de tiempo para compartir IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criterios de acceso compartido de IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non negotiable contract for data accessors) must be in place before accessing requested information.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .